Fennec Pharmaceuticals Inc (NASDAQ:FENC) COO Adrian Haigh Sells 22,222 Shares

Fennec Pharmaceuticals Inc (NASDAQ:FENC) COO Adrian Haigh sold 22,222 shares of the company’s stock in a transaction dated Friday, April 19th. The shares were sold at an average price of $9.34, for a total transaction of $207,553.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Adrian Haigh also recently made the following trade(s):

• On Monday, April 22nd, Adrian Haigh sold 22,223 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of $9.32, for a total value of $207,118.36.
• On Wednesday, April 17th, Adrian Haigh sold 22,222 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of $9.91, for a total value of $220,220.02.
• On Monday, April 15th, Adrian Haigh sold 22,222 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of $10.30, for a total transaction of $228,886.60.

Fennec Pharmaceuticals Stock Performance

Fennec Pharmaceuticals stock opened at $9.38 on Tuesday. Fennec Pharmaceuticals Inc has a 1 year low of $6.30 and a 1 year high of $11.92. The firm’s 50-day moving average is $10.05 and its 200-day moving average is $9.40. The company has a market cap of $254.20 million, a P/E ratio of -15.38 and a beta of 0.38.

Fennec Pharmaceuticals (NASDAQ:FENC) last issued its earnings results on Thursday, March 21st. The company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.12). The business had revenue of $9.74 million during the quarter, compared to the consensus estimate of $9.47 million. As a group, sell-side analysts predict that Fennec Pharmaceuticals Inc will post 0.11 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in FENC. AIGH Capital Management LLC increased its stake in shares of Fennec Pharmaceuticals by 6.9% in the third quarter. AIGH Capital Management LLC now owns 373,526 shares of the company’s stock valued at $2,805,000 after purchasing an additional 24,069 shares during the period. Gendell Jeffrey L grew its holdings in Fennec Pharmaceuticals by 0.9% in the 3rd quarter. Gendell Jeffrey L now owns 285,992 shares of the company’s stock worth $2,148,000 after buying an additional 2,579 shares in the last quarter. Worth Venture Partners LLC increased its position in Fennec Pharmaceuticals by 52.7% in the 4th quarter. Worth Venture Partners LLC now owns 141,500 shares of the company’s stock valued at $1,588,000 after acquiring an additional 48,864 shares during the period. Hartford Financial Management Inc. raised its stake in Fennec Pharmaceuticals by 4.4% during the 4th quarter. Hartford Financial Management Inc. now owns 47,348 shares of the company’s stock valued at $531,000 after acquiring an additional 2,000 shares in the last quarter. Finally, Eudaimonia Advisors LLC boosted its position in Fennec Pharmaceuticals by 90.8% during the 4th quarter. Eudaimonia Advisors LLC now owns 32,686 shares of the company’s stock worth $367,000 after acquiring an additional 15,556 shares during the period. 55.51% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

FENC has been the subject of several research analyst reports. Craig Hallum boosted their target price on shares of Fennec Pharmaceuticals from $17.00 to $18.00 and gave the stock a “buy” rating in a research report on Monday, March 18th. HC Wainwright boosted their price objective on Fennec Pharmaceuticals from $17.00 to $18.00 and gave the company a “buy” rating in a report on Thursday, April 4th. Finally, Wedbush reaffirmed an “outperform” rating and set a $16.00 target price on shares of Fennec Pharmaceuticals in a report on Monday, March 18th.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.